We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 668

Advancing New Claims Under the Lanham Act
  • Foley & Lardner LLP
  • USA
  • July 28 2016

Implementing unique litigation tactics, on June 15, 2016, Foley & Larder LLP filed a complaint under Section 337 of the Tariff Act at the


Magnum Offers New Path for Challenging AIA Decisions: Burden of Production
  • Foley & Lardner LLP
  • USA
  • July 26 2016

Yesterday, the Court of Appeals for the Federal Circuit (CAFC) held in In re Magnum Oil Tools International (Newman, O’Malley & Chen) that the burden


Can FDA Implement The BPCIA As The CAFC Suggested?
  • Foley & Lardner LLP
  • USA
  • July 21 2016

In Amgen v. Apotex, the Federal Circuit held that under the Biologics Price Competition and Innovation Act (“BPCIA”), “an applicant must provide a


En Banc CAFC Requires UCC Sale For On Sale Bar
  • Foley & Lardner LLP
  • USA
  • July 19 2016

In an en banc decision issued in The Medicines Company v. Hospira, Inc., the Federal Circuit determined that in order for a commercial transaction to


USPTO Patent Eligibility Guidance In View Of CellzDirect And Sequenom
  • Foley & Lardner LLP
  • USA
  • July 18 2016

On July 14, 2016, the USPTO issued a Memorandum to the Patent Examining Corps on patent eligibility in view of recent court decisions. The July 2016


Janssen Seeks Injunction Against Remicade Biosimilar Based On Cell Culture Patent
  • Foley & Lardner LLP
  • USA
  • July 14 2016

In a complaint filed June 14, 2016, Janssen Biotech Inc. seeks a preliminary injunction that would bar Celltrion and Hospira from selling the


The PRICED Act Would Expedite Biosimilar Market Entry
  • Foley & Lardner LLP
  • USA
  • July 12 2016

Although the 12-year exclusivity period for original biologic products was a heavily negotiated provision of the Biologics Price Competition and


CAFC Finds Cryopreservation Method Patent Eligible
  • Foley & Lardner LLP
  • USA
  • July 7 2016

The Federal Circuit ruled that the cryopreservation methods at issue in Rapid Litigation Mgmt. Ltd. v. CellzDirect Inc., are patent eligible under 35


Federal Circuit Requires 180 Day Notice For All Biosimilars, Even After Patent Dance
  • Foley & Lardner LLP
  • USA
  • July 6 2016

In Amgen v. Apotex, the Federal Circuit rejected Apotex's arguments that the 180-day pre-marketing notice requirement does not apply to biosimilar


Federal Circuit’s recent primer on patent-eligibility
  • Foley & Lardner LLP
  • USA
  • July 6 2016

A method of producing a desired population of multi-cryopreserved hepatocytes was held to be patent-eligible because the challenged claims did not